Chronic kidney disease (CKD) progresses through inflammation and fibrosis — the gradual replacement of functional kidney tissue with scar tissue. Conventional management slows progression but cannot reverse existing damage. MSC therapy is being investigated for its anti-fibrotic and anti-inflammatory properties in the kidney.
Anti-Fibrotic Mechanism
MSCs secrete HGF (hepatocyte growth factor) and PGE2 (prostaglandin E2), both of which inhibit TGF-beta — the primary driver of renal fibrosis. In animal models of CKD, MSC administration consistently reduces fibrotic area, preserves glomerular architecture, and slows GFR decline.
Clinical Evidence
Phase I/II trials in CKD patients (Stage 2–4) have demonstrated safety and modest GFR stabilization or improvement at 12 months post-treatment. Patients with diabetic nephropathy as the CKD cause show the strongest benefit — addressing both the inflammatory and fibrotic mechanisms simultaneously.
Realistic Expectations
MSC therapy for CKD aims to slow progression and reduce proteinuria — not to restore lost kidney function in Stage 4–5 disease. Patients already on dialysis or with eGFR below 15 ml/min/1.73m² are not suitable candidates. Your nephrologist's records will be reviewed before any protocol is proposed.